Evidence map›Paper›PMID 25539593›Full record

ArticleRetrovirology2014

Friend retrovirus drives cytotoxic effectors through Toll-like receptor 3.

Kathrin Gibbert, Sandra Francois, Anna M Sigmund, Michael S Harper, Bradley S Barrett, Carsten J Kirchning, Mengji Lu, Mario L Santiago, Ulf Dittmer

Open access · goldAbstract read
In one paragraph

Article in Retrovirology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Kathrin GibbertInstitute for Virology of the University Hospital in Essen, University of Duisburg-Essen, Essen, Germany. Kathrin.Gibbert@uni-due.de.
Sandra FrancoisInstitute for Virology of the University Hospital in Essen, University of Duisburg-Essen, Essen, Germany. Sandra.Francois@uk-essen.de.
Anna M SigmundInstitute for Medical Microbiology of the University Hospital in Essen, University of Duisburg-Essen, Essen, Germany. Anna.Sigmund@uk-essen.de.
Michael S HarperDepartment of Medicine, University of Colorado Denver, Aurora, CO, 80045, USA. Michael.Harper@ucdenver.com.
Bradley S BarrettDepartment of Medicine, University of Colorado Denver, Aurora, CO, 80045, USA. Brad.Barrett@ucdenver.com.
Carsten J KirchningInstitute for Medical Microbiology of the University Hospital in Essen, University of Duisburg-Essen, Essen, Germany. Carsten.Kirschning@uk-essen.de.
Mengji LuInstitute for Virology of the University Hospital in Essen, University of Duisburg-Essen, Essen, Germany. Mengji.Lu@uni-due.de.
Mario L SantiagoDepartment of Medicine, University of Colorado Denver, Aurora, CO, 80045, USA. Mario.Santiago@ucdenver.com.
Ulf DittmerInstitute for Virology of the University Hospital in Essen, University of Duisburg-Essen, Essen, Germany. Ulf.Dittmer@uni-due.de.
University of Duisburg-Essen · DEUniversity of Colorado Denver · US

Funding

Medical Scientist Training ProgramT32GM008497 · NIGMS · UNIVERSITY OF COLORADO DENVER · PI WILSON, CARA C. · 1993 to 2022
$15.2M
Innate Restriction Factor Modulation of Retrovirus-specific Humoral ImmunityR01AI090795 · NIAID · UNIVERSITY OF COLORADO DENVER · PI SANTIAGO, MARIO LUIS · 2010 to 2013
$2.8M
Immunological impact of Tetherin retrovirus restrictionR21AI112418 · NIAID · UNIVERSITY OF COLORADO DENVER · PI SANTIAGO, MARIO LUIS · 2014 to 2015
$427k
NIAID NIH HHS R01 AI090795NIAID NIH HHS R21 AI112418NIGMS NIH HHS T32 GM008497
6 · The paper itself

Abstract

backgroundPathogen recognition drives host defense towards viral infections. Specific groups rather than single members of the protein family of pattern recognition receptors (PRRs) such as membrane spanning Toll-like receptors (TLRs) and cytosolic helicases might mediate sensing of replication intermediates of a specific virus species. TLR7 mediates host sensing of retroviruses and could significantly influence retrovirus-specific antibody responses. However, the origin of efficient cell-mediated immunity towards retroviruses is unknown. Double-stranded RNA intermediates produced during retroviral replication are good candidates for immune stimulatory viral products. Thus, we considered TLR3 as primer of cell-mediated immunity against retroviruses in vivo.

resultsInfection of mice deficient in TLR3 (TLR3(-/-)) with Friend retrovirus (FV) complex revealed higher viral loads during acute retroviral infection compared to wild type mice. TLR3(-/-) mice exhibited significantly lower expression levels of type I interferons (IFNs) and IFN-stimulated genes like Pkr or Ifi44, as well as reduced numbers of activated myeloid dendritic cells (DCs) (CD86(+) and MHC-II(+)). DCs generated from FV-infected TLR3(-/-) mice were less capable of priming virus-specific CD8(+) T cell proliferation. Moreover, cytotoxicity of natural killer (NK) cells as well as CD8(+) T cells were reduced in vitro and in vivo, respectively, in FV-infected TLR3(-/-) mice.

conclusionsTLR3 mediates antiretroviral cytotoxic NK cell and CD8(+) T cell activity in vivo. Our findings qualify TLR3 as target of immune therapy against retroviral infections.

Indexed as

AnimalsCD8-Positive T-LymphocytesFemaleFriend murine leukemia virusKiller Cells, NaturalLeukemia, ExperimentalMice, Inbred C57BLMice, KnockoutRetroviridae InfectionsToll-Like Receptor 3Tumor Virus InfectionsViral LoadToll-Like Receptor 3

Identifiers

PMID25539593
PMCPMC4299798
OpenAlexW2106047550

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.